COMMUNIQUÉS West-GlobeNewswire

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development
23/06/2025
Dr. Moraitis brings deep experience in endocrinology to his role leading clinical development for MBX’s lead product candidate, canvuparatide CARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq [...]
Chiesi Global Rare Diseases Awards Research Grants to Advance Innovation in Lysosomal Diseases
23/06/2025
PARMA, Italy, June 23, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today [...]
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
23/06/2025
RESEARCH TRIANGLE PARK, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing gene therapies for the treatment of inherited retinal [...]
Optime Care Partners with Tilde Sciences as Exclusive Specialty Pharmacy Provider for Vecamyl
23/06/2025
ST. LOUIS, June 23, 2025 (GLOBE NEWSWIRE) -- Optime Care , AscellaHealth’s Specialty Pharmacy, is pleased to announce an expanded partnership with Tilde Sciences LLC (“Tilde”), effective June 23, 2025. Under this [...]
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
23/06/2025
Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia [...]
Data from the Phase 2 Clinical Trial of CX11/VCT220 in China Presented at ADA 2025
23/06/2025
Patients treated with CX11 (also designated as VCT220) achieved a 9.7% and 9.4% decrease in body weight from baseline after 16 weeks (p≤0.001) in the 160 mg fast and slow titration cohorts, respectively. Results suggest [...]
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
23/06/2025
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) [...]
Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
23/06/2025
Vancouver, Canada, June 23, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
New DoseSpot Analysis of 100,000 GLP-1 Prescriptions Finds That Patients Overpaid by $10.2M Collectively
23/06/2025
92 percent of prescriptions could have been filled at a lower price, with better information on pricing, dispensing options and manufacturer cost-savings programs BOSTON, June 23, 2025 (GLOBE NEWSWIRE) -- DoseSpot , [...]
Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052
23/06/2025
- Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) - WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. ( [...]
ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)
23/06/2025
New study arm (Part D) is part of the broad clinical development plan of the ITM-91/ITM-94 theranostic program in patients with Carbonic Anhydrase IX (CAIX)-expressing tumors Part D builds on promising imaging data [...]
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
23/06/2025
REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and [...]
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
23/06/2025
REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a [...]
Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine
23/06/2025
Final analysis of PEARL real world migraine prevention study presented at 11th Congress of the European Academy of Neurology (EAN 2025) Congress in Helsinki 1 , 2 Fremanezumab demonstrated sustained effectiveness and a [...]
141,959 Orion Corporation A shares converted into B shares
23/06/2025
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 23 June 2025 at 9.30 EEST 141,959 Orion Corporation A shares converted into B shares In accordance with [...]
Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML
23/06/2025
60% (12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R 2 ) EO2463 plus R 2 was well tolerated in patients with follicular and marginal zone lymphoma EO2463 plus [...]
AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
23/06/2025
PRESS RELEASE NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB’S POTENTIAL FOR THE TREATMENT OF ALZHEIMER’S DISEASE THROUGH A DUAL MECHANISM OF COGNITIVE ENHANCEMENT AND NEUROPROTECTION THIS [...]
AB Science - De nouvelles données évaluées par des pairs apportent des preuves solides du potentiel du masitinib dans le traitement de la maladie d’Alzheimer
23/06/2025
COMMUNIQUE DE PRESSE DE NOUVELLES DONNÉES ÉVALUÉES PAR DES PAIRS APPORTENT DES PREUVES SOLIDES DU POTENTIEL DU MASITINIB DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER GRÂCE À UN DOUBLE MÉCANISME D'AMÉLIORATION COGNITIVE [...]
Opterion Health AG Appoints Industry Leaders Rice Powell and Mark Hahn to Board of Directors
23/06/2025
MUTTENZ, Switzerland, June 23, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a Swiss-based life sciences company developing a next-generation, non-glucose based peritoneal dialysis (PD) solution, today announced the [...]

Pages